Affiliations
AffiliationsItem in Clipboard
Guideline-discordant inhaler regimens after COPD hospitalization: associations with rurality, drive time to care, and fragmented care - a United States cohort studyArianne K Baldomero et al. Lancet Reg Health Am. 2023.
doi: 10.1016/j.lana.2023.100597. eCollection 2023 Oct. AffiliationsItem in Clipboard
AbstractBackground: Many patients receive guideline-discordant inhaler regimens after chronic obstructive pulmonary disease (COPD) hospitalization. Geography and fragmented care across multiple providers likely influence prescription of guideline-discordant inhaler regimens, but these have not been comprehensively studied. We assessed patient-level differences in guideline-discordant inhaler regimens by rurality, drive time to pulmonary specialty care, and fragmented care.
Methods: Retrospective cohort analysis using national Veterans Health Administration (VA) data among patients who received primary care and prescriptions from the VA. Patients hospitalized for COPD exacerbation between 2017 and 2020 were assessed for guideline-discordant inhaler regimens in the subsequent 3 months. Guideline-discordant inhaler regimens were defined as short-acting inhaler/s only, inhaled corticosteroid (ICS) monotherapy, long-acting beta-agonist (LABA) monotherapy, ICS + LABA, long-acting muscarinic antagonist (LAMA) monotherapy, or LAMA + ICS. Rural residence and drive time to the closest pulmonary specialty care were obtained from geocoded addresses. Fragmented care was defined as hospitalization outside the VA. We used multivariable logistic regression models to assess associations between rurality, drive time, fragmentated care, and guideline-discordant inhaler regimens. Models were adjusted for age, sex, race/ethnicity, Charlson Comorbidity Index, Area Deprivation Index, and region.
Findings: Of 33,785 patients, 16,398 (48.6%) received guideline-discordant inhaler regimens 3 months after hospitalization. Rural residents had higher odds of guideline-discordant inhalers regimens compared to their urban counterparts (adjusted odds ratio [aOR] 1.18 [95% CI: 1.12-1.23]). The odds of receiving guideline-discordant inhaler regimens increased with longer drive time to pulmonary specialty care (aOR 1.38 [95% CI: 1.30-1.46] for drive time >90 min compared to <30 min). Fragmented care was also associated with higher odds of guideline-discordant inhaler regimens (aOR 1.56 [95% CI: 1.48-1.63]).
Interpretation: Rurality, long drive time to care, and fragmented care were associated with greater prescription of guideline-discordant inhaler regimens after COPD hospitalization. These findings highlight the need to understand challenges in delivering evidence-based care.
Funding: NIHNCATS grants KL2TR002492 and UL1TR002494.
Keywords: Access to care; Drive time to care; Health care disparity; Rural health; Veterans affairs.
Conflict of interest statementAKB reported grants from the National Institutes of Health. CHS reported grants from the Health Resources and Services Administration, Federal Office of Rural Health Policy, the National Institutes of Health and the CDC; payment or honoraria from Iowa Primary Care Association, Southern Gerontological Society, and the University of Michigan; and leadership or fiduciary role in the National Rural Health Association Board of Trustees. KMK reported personal fees from Nuvaira and Organicell (Data and Safety Monitoring Boards) outside of this work; consulting fees from Allergan/AbbVie and leadership or fiduciary role in the American Thoracic Society Proposal Review Committee, the American Thoracic Society Clinical Problems, and the Assembly Planning Committee.
FiguresFig. 1
Flow diagram of patients hospitalized…
Fig. 1
Flow diagram of patients hospitalized for COPD exacerbation included in the analyses .
Fig. 1Flow diagram of patients hospitalized for COPD exacerbation included in the analyses.
Fig. 2
Inhaler regimens at 3 months…
Fig. 2
Inhaler regimens at 3 months after COPD hospitalization (N = 33,785) . Abbreviations:…
Fig. 2Inhaler regimens at 3 months after COPD hospitalization (N = 33,785). Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting beta-agonist; and LAMA, long-acting muscarinic antagonist. Black bars represent guideline-discordant inhaler regimens. White bars represent guideline-concordant inhaler regimens.
Similar articlesSamp JC, Joo MJ, Schumock GT, Calip GS, Pickard AS, Lee TA. Samp JC, et al. Pharmacotherapy. 2017 Apr;37(4):447-455. doi: 10.1002/phar.1913. Pharmacotherapy. 2017. PMID: 28226405
Lane DC, Stemkowski S, Stanford RH, Tao Z. Lane DC, et al. J Manag Care Spec Pharm. 2018 Nov;24(11):1165-1172. doi: 10.18553/jmcp.2018.24.11.1165. J Manag Care Spec Pharm. 2018. PMID: 30362922 Free PMC article.
Maqsood U, Ho TN, Palmer K, Eccles FJ, Munavvar M, Wang R, Crossingham I, Evans DJ. Maqsood U, et al. Cochrane Database Syst Rev. 2019 Mar 6;3(3):CD012930. doi: 10.1002/14651858.CD012930.pub2. Cochrane Database Syst Rev. 2019. PMID: 30839102 Free PMC article.
Petite SE. Petite SE. Ann Pharmacother. 2017 Aug;51(8):696-705. doi: 10.1177/1060028017705149. Epub 2017 Apr 14. Ann Pharmacother. 2017. PMID: 28410560 Review.
Lai CC, Chen CH, Chen KH, Wang CY, Huang TM, Wang YH, Wang HC. Lai CC, et al. Life (Basel). 2022 Jan 25;12(2):173. doi: 10.3390/life12020173. Life (Basel). 2022. PMID: 35207460 Free PMC article. Review.
Kim SH, Park JE, Yang B, Kim SY, Kim YY, Park JH. Kim SH, et al. BMJ Open Respir Res. 2024 Jun 18;11(1):e002391. doi: 10.1136/bmjresp-2024-002391. BMJ Open Respir Res. 2024. PMID: 38897613 Free PMC article.
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.3